LOTENSIN HCT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lotensin Hct, and what generic alternatives are available?
Lotensin Hct is a drug marketed by Validus Pharms and is included in one NDA.
The generic ingredient in LOTENSIN HCT is benazepril hydrochloride; hydrochlorothiazide. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the benazepril hydrochloride; hydrochlorothiazide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lotensin Hct
A generic version of LOTENSIN HCT was approved as benazepril hydrochloride; hydrochlorothiazide by ANI PHARMS on February 11th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LOTENSIN HCT?
- What are the global sales for LOTENSIN HCT?
- What is Average Wholesale Price for LOTENSIN HCT?
Summary for LOTENSIN HCT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 134 |
| Clinical Trials: | 13 |
| Patent Applications: | 2,784 |
| Drug Prices: | Drug price information for LOTENSIN HCT |
| What excipients (inactive ingredients) are in LOTENSIN HCT? | LOTENSIN HCT excipients list |
| DailyMed Link: | LOTENSIN HCT at DailyMed |
Recent Clinical Trials for LOTENSIN HCT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Nanjing Children's Hospital | Phase 2 |
| University of Nebraska | Phase 4 |
| Henan University of Traditional Chinese Medicine | Phase 1/Phase 2 |
Pharmacology for LOTENSIN HCT
| Drug Class | Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
| Physiological Effect | Decreased Blood Pressure Increased Diuresis |
US Patents and Regulatory Information for LOTENSIN HCT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Validus Pharms | LOTENSIN HCT | benazepril hydrochloride; hydrochlorothiazide | TABLET;ORAL | 020033-001 | May 19, 1992 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Validus Pharms | LOTENSIN HCT | benazepril hydrochloride; hydrochlorothiazide | TABLET;ORAL | 020033-003 | May 19, 1992 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Validus Pharms | LOTENSIN HCT | benazepril hydrochloride; hydrochlorothiazide | TABLET;ORAL | 020033-002 | May 19, 1992 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Validus Pharms | LOTENSIN HCT | benazepril hydrochloride; hydrochlorothiazide | TABLET;ORAL | 020033-004 | May 19, 1992 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LOTENSIN HCT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Validus Pharms | LOTENSIN HCT | benazepril hydrochloride; hydrochlorothiazide | TABLET;ORAL | 020033-001 | May 19, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Validus Pharms | LOTENSIN HCT | benazepril hydrochloride; hydrochlorothiazide | TABLET;ORAL | 020033-003 | May 19, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Validus Pharms | LOTENSIN HCT | benazepril hydrochloride; hydrochlorothiazide | TABLET;ORAL | 020033-004 | May 19, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Validus Pharms | LOTENSIN HCT | benazepril hydrochloride; hydrochlorothiazide | TABLET;ORAL | 020033-002 | May 19, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LOTENSIN HCT
See the table below for patents covering LOTENSIN HCT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Finland | 822770 | ⤷ Sign Up | |
| Greece | 77256 | ⤷ Sign Up | |
| Spain | 8703859 | ⤷ Sign Up | |
| Japan | S5838260 | BENZAZEPIN-2-ONE, MANUFACTURE, MEDICINE AND THERAPEUTICAL USE | ⤷ Sign Up |
| Argentina | 243163 | PROCEDIMIENTO PARA OBTENER NOVEDOSOS ACIDOS 3-(5-AMINOPENTIL)-AMINO-1-BENZAZEPIN-2-ONA-1-ALCANOICOS. (3-AMINO-(1)-BENZAZEPIN-2-ONE-1-ALKANOIC ACIDS) | ⤷ Sign Up |
| Norway | 166232 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
